Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers

Trial Profile

Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Pharmacokinetics
  • Sponsors Holy Stone Healthcare
  • Most Recent Events

    • 21 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 18 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 18 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top